JPH0148883B2 - - Google Patents

Info

Publication number: JPH0148883B2
Authority: JP; Japan
Prior art keywords: pantetheine; sulfonic acid; liver; administration; serum
Prior art date: 1981-12-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP19439281A

Other languages

English (en)

Japanese (ja)

Other versions

JPS5896020A (ja

Inventor

Tetsuya Suga

Manabu Katsumata

Tomoyasu Tashiro

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sogo Pharmaceutical Co Ltd

Original Assignee

Sogo Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-12-04

Filing date

1981-12-04

Publication date

1989-10-20

1981-12-04 Application filed by Sogo Pharmaceutical Co Ltd filed Critical Sogo Pharmaceutical Co Ltd

1981-12-04 Priority to JP19439281A priority Critical patent/JPS5896020A/ja

1982-11-18 Priority to GB08232874A priority patent/GB2110536B/en

1982-11-30 Priority to CH6941/82A priority patent/CH652924A5/fr

1982-12-02 Priority to IT49605/82A priority patent/IT1149398B/it

1982-12-02 Priority to FR8220179A priority patent/FR2517542B1/fr

1982-12-03 Priority to DE19823244806 priority patent/DE3244806A1/de

1983-06-07 Publication of JPS5896020A publication Critical patent/JPS5896020A/ja

1984-04-09 Priority to US06/598,238 priority patent/US4568683A/en

1989-10-20 Publication of JPH0148883B2 publication Critical patent/JPH0148883B2/ja

Status Granted legal-status Critical Current

Links

-1 alkali metal salt Chemical class 0.000 claims description 27
239000003814 drug Substances 0.000 claims description 11
229940079593 drug Drugs 0.000 claims description 10
208000019423 liver disease Diseases 0.000 claims description 8
239000004480 active ingredient Substances 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
229910052783 alkali metal Inorganic materials 0.000 claims description 3
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 3
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 14
206010067125 Liver injury Diseases 0.000 description 13
231100000234 hepatic damage Toxicity 0.000 description 13
230000008818 liver damage Effects 0.000 description 13
210000002966 serum Anatomy 0.000 description 13
150000001875 compounds Chemical class 0.000 description 12
230000000694 effects Effects 0.000 description 11
DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 9
DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 9
239000011581 pantethine Substances 0.000 description 9
229960000903 pantethine Drugs 0.000 description 9
235000008975 pantethine Nutrition 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 8
CILGDYPFLJJNKT-NAWJVIAPSA-L calcium;(2r)-2,4-dihydroxy-3,3-dimethyl-1-oxo-1-[[3-oxo-3-(2-sulfonatosulfanylethylamino)propyl]amino]butane Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSS([O-])(=O)=O.OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSS([O-])(=O)=O CILGDYPFLJJNKT-NAWJVIAPSA-L 0.000 description 7
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
229930195712 glutamate Natural products 0.000 description 6
238000000034 method Methods 0.000 description 6
239000000126 substance Substances 0.000 description 6
208000015163 Biliary Tract disease Diseases 0.000 description 5
241000700159 Rattus Species 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
239000003826 tablet Substances 0.000 description 5
102000002260 Alkaline Phosphatase Human genes 0.000 description 4
108020004774 Alkaline Phosphatase Proteins 0.000 description 4
108090000340 Transaminases Proteins 0.000 description 4
102000003929 Transaminases Human genes 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
239000011575 calcium Substances 0.000 description 4
239000008187 granular material Substances 0.000 description 4
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
ZNXZGRMVNNHPCA-UHFFFAOYSA-N Pantetheine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-UHFFFAOYSA-N 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
235000013355 food flavoring agent Nutrition 0.000 description 3
239000008101 lactose Substances 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
235000002767 Daucus carota Nutrition 0.000 description 2
244000000626 Daucus carota Species 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
WMFYOYKPJLRMJI-UHFFFAOYSA-N Lercanidipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 WMFYOYKPJLRMJI-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
235000019658 bitter taste Nutrition 0.000 description 2
159000000007 calcium salts Chemical class 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
239000005516 coenzyme A Substances 0.000 description 2
229940093530 coenzyme a Drugs 0.000 description 2
KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
108010012204 glutamate aminotransferase Proteins 0.000 description 2
230000009931 harmful effect Effects 0.000 description 2
230000035876 healing Effects 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
ZNXZGRMVNNHPCA-VIFPVBQESA-N pantetheine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-VIFPVBQESA-N 0.000 description 2
GHOKWGTUZJEAQD-UHFFFAOYSA-N pantothenic acid Chemical compound OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
108010025593 phenylalanine (histidine) aminotransferase Proteins 0.000 description 2
238000012360 testing method Methods 0.000 description 2
QMVCRMKELLPOMY-UHFFFAOYSA-N 2-aminoethanethiol;sulfuric acid Chemical compound NCCS.OS(O)(=O)=O QMVCRMKELLPOMY-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
241000725101 Clea Species 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical class O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
206010047163 Vasospasm Diseases 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009692 acute damage Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
244000309464 bull Species 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000032677 cell aging Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
238000002795 fluorescence method Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
150000002432 hydroperoxides Chemical class 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000003859 lipid peroxidation Effects 0.000 description 1
210000001853 liver microsome Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000000384 rearing effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
238000010998 test method Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
239000011345 viscous material Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
210000004885 white matter Anatomy 0.000 description 1

Landscapes

Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP19439281A 1981-12-04 1981-12-04 肝障害改善薬 Granted JPS5896020A (ja)

Priority Applications (7)

Application Number	Priority Date	Filing Date	Title
JP19439281A JPS5896020A (ja)	1981-12-04	1981-12-04	肝障害改善薬
GB08232874A GB2110536B (en)	1981-12-04	1982-11-18	Pharmaceutical compositions containing pantetheine-s-sulphonic acid
CH6941/82A CH652924A5 (fr)	1981-12-04	1982-11-30	Produits pharmaceutique ameliorant le metabolisme des lipides.
IT49605/82A IT1149398B (it)	1981-12-04	1982-12-02	Farmaco che migliora il metabolismo di lipidi contenente acido pantetei n-s-solfonico
FR8220179A FR2517542B1 (fr)	1981-12-04	1982-12-02	Medicament pour l'amelioration du metabolisme lipidique
DE19823244806 DE3244806A1 (de)	1981-12-04	1982-12-03	Den lipid-stoffwechsel verbesserndes arzneimittel
US06/598,238 US4568683A (en)	1981-12-04	1984-04-09	Lipid metabolism with pantetheine-S-sulfonic acid

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP19439281A JPS5896020A (ja)	1981-12-04	1981-12-04	肝障害改善薬

Publications (2)

Publication Number	Publication Date
JPS5896020A JPS5896020A (ja)	1983-06-07
JPH0148883B2 true JPH0148883B2 (de)	1989-10-20

Family

ID=16323825

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP19439281A Granted JPS5896020A (ja)	1981-12-04	1981-12-04	肝障害改善薬

Country Status (1)

Country	Link
JP (1)	JPS5896020A (de)

1981
- 1981-12-04 JP JP19439281A patent/JPS5896020A/ja active Granted

Also Published As

Publication number	Publication date
JPS5896020A (ja)	1983-06-07

Publication	Publication Date	Title
CA2123232C (fr)	2005-02-15	Compositions pharmaceutiques a base d'ebastine ou de ses analogues
JP2002537258A5 (de)	2011-08-25
US4428963A (en)	1984-01-31	Novel thiophene derivatives
JPS63264421A (ja)	1988-11-01	高脂質血症治療剤
CA2679030A1 (en)	2004-07-01	Alpha-2-delta ligand to treat lower urinary track symptoms
JP2021530488A (ja)	2021-11-11	可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール
JPS5925794B2 (ja)	1984-06-21	尿素のヘテロシクリルカルボニル誘導体
EP0132994B1 (de)	1988-06-01	Verbindungen zur Verminderung des Lipidspiegels
US4855293A (en)	1989-08-08	Anti-inflammatory compositions comprising a systemic non-steroidal anti-inflammatory drug and a cyclopentyl ether
JPH0148883B2 (de)	1989-10-20
US4067998A (en)	1978-01-10	2-((3,5-Di-tert-butylphenyl)thio) alkanoic acids and derivatives
JPH0152366B2 (de)	1989-11-08
EP1051172B1 (de)	2004-12-22	Methode zur behandlung der chronischen obstruktiven bronchopneumopathie
JPS63310825A (ja)	1988-12-19	医薬に有用な二環式化合物のｎ−イミダゾリル誘導体
US3870792A (en)	1975-03-11	Certain dihydrophthalizines for treating hemorrhage and thrombosis
FR2527078A1 (fr)	1983-11-25	Compositions pharmaceutiques anti-ulceres
US4086354A (en)	1978-04-25	Novel anti-hypertensive compositions
US4568683A (en)	1986-02-04	Lipid metabolism with pantetheine-S-sulfonic acid
US6034126A (en)	2000-03-07	Method for treating glycol poisoning
JPH10101556A (ja)	1998-04-21	ファクターｄ阻害剤
US4579870A (en)	1986-04-01	Aminoalkyl phenyl selenides for the treatment of hypertension and nervous system dysfunctions
JPH0343249B2 (de)	1991-07-01
US4906668A (en)	1990-03-06	Aminoalkyl phenyl selenides for the treatment of hypertension and nervous system dysfunctions
FR2727111A1 (fr)	1996-05-24	Nouveaux analogues soufres d'aminoacides, leur procede de preparation et leurs applications comme medicaments
JPS58164507A (ja)	1983-09-29	ジベンゾシクロヘプテニリデン類による免疫変化剤